BARCELONA, Spain, March 23 -- The Autonomous University of Barcelona issued the following news:

* * *

UAB compound designated orphan drug to advance towards a new treatment for spinal cord injury

*

The European Medicines Agency (EMA) has designated as an orphan drug a compound based on the bioactive lipid molecule Maresin-1 (MaR1), currently being investigated by a research team from the UAB for the treatment of spinal cord injuries.